Heading: |
Drugs: Prices |
Question ID: |
1824866 |
UIN: |
69183 |
House: |
Commons |
Date tabled: |
2025-07-18 |
Asking Member ID: |
5312 |
Asking Member display name: |
Sadik Al-Hassan
|
Asking Member handle: |
|
Asking Member Twitter reference: |
Sadik Al-Hassan
|
Member interest: |
false |
Question text: |
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 June 2025 to Question 54542 on Drug Prices, how many of the commercial arrangements involving indications-specific pricing were for indications for (a) rare and (b) ult |
Is named day: |
false |
Date of holding answer: |
|
Date answered: |
2025-08-04 |
Date answer corrected: |
|
Is holding answer: |
false |
Is correcting answer: |
false |
Answering Member ID: |
4444 |
Answering Member display name: |
Karin Smyth
|
Answering Member handle: |
karinsmyth
|
Answering Member Twitter reference: |
@karinsmyth
|
Correcting Member ID: |
|
Correcting Member display name: |
|
Correcting Member handle: |
|
Correcting Member Twitter reference: |
|
Answer text: |
Between January 2020 and March 2025, NHS England entered into 62 commercial agreements involving indication-specific pricing for cancer indications. Of these:60 were for indications classified as rare; andof those 60, two were for indications classified a... |
Original answer text: |
|
Comparable answer text: |
|
Answering body ID: |
17 |
Answering body name: |
Department of Health and Social Care |
Tweeted: |
true |